In vitro study demonstrates enhanced bioactivity and preserved viability in gastrointestinal cells at low bismuth concentrations, highlighting potential for localized soft-tissue repair.
Bismuth(III)-doped 13–93 silicate bioactive glass powders were synthesized via a sol–gel route with Bi₂O₃ contents ranging from 0.1 to 5 wt% using two different precursors, BiCl₃ and Bi(NO₃)₃.5H 2 O. Structural characterization by X-ray diffraction and FTIR confirmed the predominantly amorphous nature of the glasses and the formation of a typical silicate network structure. In vitro bioactivity studies performed in simulated body fluid (SBF) and phosphate-buffered saline (PBS) demonstrated the formation of a calcium phosphate–rich apatite layer on the surface of the glasses, confirming their bioactive behavior. FTIR and SEM analyses indicated apatite-like calcium phosphate formation after immersion, with Bi 3+ -doped compositions showed slightly enhanced apatite formation. Cytocompatibility assessments using multiple gastrointestinal-relevant cell models, including AGS, HIF, HISMC, and HEK-293 cells, showed that high Bi 3+ contents (≥1 wt%) resulted in reduced cell viability, whereas low Bi 3+ concentrations (0.1–0.5 wt%) maintained excellent cytocompatibility. Overall, the results indicate that low-Bi 3+ -doped 13–93 bioactive glasses combine bioactivity and cytocompatibility, suggesting their potential as multifunctional biomaterials for localized soft tissue applications.
No takes yet. Share an insight, caveat, or question.
Deliormanlı et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: